As of March 31, 2024, Pyxis Oncology had cash and cash equivalents, including restricted cash, and short-term investments of $158.5 million. During Q1 2024, the Company raised gross proceeds of $10.8 million via an at-the-market offering, completed a $50 million private placement, and sold the Company’s rights to royalties from the commercialization of Beovu and another asset for a one-time payment of $8 million to Novartis. Pyxis Oncology expects to have the cash runway to fund operations into 2H 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PYXS:
- Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024
- Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference
- PYXS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Pyxis Oncology assumed with a Buy at Jefferies
- Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)